Study looks at immune cells in active lupus
Part of Immune system & allergy, Skin clinical trials.
This trial studies “myeloid-derived suppressor cells,” a type of immune cell, in people with active lupus, to better understand how the immune system is behaving. It may help researchers find ways to improve treatment in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have active systemic lupus erythematosus (lupus) based on a disease activity score (SLEDAI) of 1 or higher.
- Be able and willing to sign a written informed consent form.
- Do not have a current or recent infection (chronic or acute).
- Do not have any other autoimmune condition that is active right now.
- Do not have active cancer right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune cells in people with certain autoimmune diseases or immune deficiencies. The goal is to understand how these cells work, which may help improve future treatments.
This study looks at how certain immune cells (natural killer T cells) behave in people with systemic lupus, by measuring specific immune receptor markers in blood. It may help researchers better understand lupus and how it can connect with other conditions like antiphospholipid syndrome or Sjögren’s.
This study tests whether a special type of stem cell treatment (called UC-MSC) can help calm lupus when standard medicines aren't enough. It's for people with active lupus who have tried other non-steroid medications.
This trial is testing a new type of immune cell therapy (called CD19 universal CAR-γδT cells) for people with active lupus that hasn't been well controlled by standard treatments. The goal is to see if these specially designed cells can calm the immune system and reduce lupus symptoms.
This research study aims to better understand systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system attacks its own tissues. Researchers will evaluate patients with lupus, study genetic factors, and perform optional imaging tests to learn how the disease affects blood vessels and the heart.
This study tests a new treatment called CD19 CAR-T, which reprograms your own immune cells to attack lupus. It is for people with active lupus that has not responded well to standard therapies.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.